Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin

November 26, 2020 Auto Bot Avastin, Biosimilars, cancer, EMA, Submits 0

Shots:

  • The company has submitted an MAAA for BAT1706 to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the EU Member States, Iceland, Norway, and Liechtenstein
  • The submission of the MAA for BAT1706 marks it as the first ex-China MAA/ BLA submission. The BLA of the biosimilar for metastatic carcinoma of the colon or rectum and NSCLC is under NMPA’s review
  • The company plans to submit a BLA for BAT1706 to the US FDA by the end of 2020. Bevacizumab is a mAb that targets VEGF thus reduces neovascularization, thereby inhibiting tumor growth

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

The post Bio-Thera Reports MAA Submission to EMA for BAT1706 a Proposed Biosimilar to Avastin first appeared on PharmaShots.